⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446743 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1190430 | 0.97 | — | — | |
| SCHEMBL2760285 | 0.90 | — | — | |
| SCHEMBL18072564 | 0.88 | SOS1 (0.34) | — | |
| SCHEMBL20706020 | 0.88 | SOS1 (0.34) | — | |
| SCHEMBL17067231 | 0.88 | SOS1 (0.34) | — | |
| SCHEMBL1665473 | 0.88 | — | — | |
| SCHEMBL17067163 | 0.88 | SOS1 (0.34) | — | |
| SCHEMBL16070318 | 0.88 | — | — | |
| SCHEMBL17067233 | 0.88 | SOS1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2024-03-21 | — | — | US | disclosed |
| EP-3470407-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11751592-B2 | Sweetness and taste improvement of steviol glycoside or mogroside sweeteners | THE COCA-COLA COMPANY (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-111417620-B | Creatine prodrugs, compositions thereof, and methods of use | 奥特吉尼克斯制药公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4228630-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | Albert-Ludwigs-Universität Freiburg (DE) | 2023-08-23 | — | — | EP | disclosed |
| CN-109219355-B | Sweetness and taste improvement of steviol glycoside or mogroside sweeteners | 可口可乐公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2022-07-21 | — | — | US | disclosed |
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-109820853-B | Use of substituted heterocyclic compounds for the treatment of cancer | VM肿瘤药物有限责任公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | MIDCAP FINANCIAL TRUST | 2004-12-16 | — | — | US | disclosed |
| WO-2004103366-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | RIGEL PHARMACEUTICALS (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040236112-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | MIDCAP FINANCIAL TRUST | 2004-11-25 | — | — | US | disclosed |
| WO-2004099164-A1 | SUBSTITUTED DIPHENYL ISOXAZOLES, PYRAZOLES AND OXADIAZOLES USEFUL FOR TREATING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099165-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1451162-A1 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS | 2004-07-22 | — | — | US | disclosed |
| US-6759538-B2 | PREVENTION INFECTIONS OF HEPATITIS C VIRUS | RIGEL PHARMACEUTICALS, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20030165561-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | MIDCAP FINANCIAL TRUST | 2003-09-04 | — | — | US | disclosed |
| WO-2003040112-A1 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |